NCT06155760 is a NA clinical trial of Prednisolone in Severe Alcoholic Hepatitis, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT06155760?

NCT06155760 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT06155760?

Interventions in NCT06155760: Prednisolone, Standard Medical therapy, Placebo.

What condition does NCT06155760 study?

NCT06155760 studies Severe Alcoholic Hepatitis.

Is NCT06155760 still recruiting?

NCT06155760 is currently status unknown. Last updated 4 December 2023.

Last reviewed 2023-12-04 · How we verify

NCT06155760

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

Status unknown NA Last updated 4 December 2023

What this trial tests

NA trial testing Prednisolone in Severe Alcoholic Hepatitis in 150 participants. Status unknown.

Timeline

25 November 2023

Primary endpoint
27 February 2025

27 February 2025

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	25 November 2023
Primary completion	27 February 2025
Estimated completion	27 February 2025
Sites	1 location across India

Drugs / interventions tested

Prednisolone — full drug profile →
Standard Medical therapy — full drug profile →
Placebo

Conditions studied

Severe Alcoholic Hepatitis — all drugs for Severe Alcoholic Hepatitis →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 60, any sex, with Severe Alcoholic Hepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Severity of alcoholic hepatitis is defined by Maddrey's discriminant function, value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse prognosis with one month mortality of 30%-50%. Prednisolone (40 mg/day) given orally should be considered to improve 28-day mortality in patients with severe AH. Abstinence is key to long-term survival. According to current protocol, we discontinue the treatment after 28 days but only 15 % patient is achieving the DF \< 32 after 28 days of treatment. The aim of this study is to evaluate the role of extended low dose prednisolone (10mg) in achieving remission by day-90 in steroid responsive severe alcoholic hepatitis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current Clinical Trials for Alcohol-Associated Hepatitis.
Rady ED, Anouti A, Mitchell MC, Cotter TG. · · 2026 · cited 3× · PMID 40254132 · DOI 10.1016/j.ajpath.2025.03.009
Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials.
Ma J, Gao H, Zeng G, Huda N, et al · · 2025 · PMID 41163775 · DOI 10.1007/s11901-025-00703-9

Verify or expand the search:

Other trials of Prednisolone

Trials testing the same drug.

NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07210008 — "Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity · Phase 3 · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07052929 — Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators · Phase 1, PHASE2 · recruiting
NCT07252271 — Very Low Dose Prednisolone on Newly Diagnosed Rheumatoid Arthritis · Phase 4 · not yet recruiting

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06155760 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 4 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06155760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing